Apyx Medical Reports Strong Preliminary Q4 2025 Revenue Growth, Driven by AYON Launch

summarizeSummary

Apyx Medical reported robust preliminary revenue for Q4 and full year 2025, with Q4 total revenue increasing 34% year-over-year, largely due to the successful launch of the AYON Body Contouring System.

check_boxKey Events

• Strong Q4 2025 Revenue Growth

  Total preliminary revenue for the fourth quarter of 2025 is expected to be in the range of $19.0 to $19.2 million, representing an increase of approximately 34% year-over-year.

• Surgical Aesthetics Segment Drives Growth

  Surgical Aesthetics revenue is projected to increase by approximately 38% year-over-year in Q4, with U.S. Surgical Aesthetics revenue up approximately 51% following the AYON launch.

• Positive Full Year 2025 Performance

  Preliminary total revenue for the full year 2025 is expected to be in the range of $52.7 to $52.9 million, representing an increase of approximately 10% from the prior year.

• Strategic Product Launch Success

  The CEO highlighted the immediate momentum from the AYON commercial launch and the company's strong position to capitalize on increasing aesthetic surgical procedures, partly due to GLP-1 therapies.

auto_awesomeAnalysis

Apyx Medical's preliminary Q4 2025 revenue results indicate significant year-over-year growth, primarily fueled by the successful commercial launch of its AYON Body Contouring System. The substantial increase in Surgical Aesthetics revenue, particularly in the U.S., suggests strong market adoption for their new product and effective execution of their growth strategy. This positive momentum, coupled with favorable industry trends like GLP-1 therapy adoption, positions the company for continued growth. Investors should monitor the full audited results in March for confirmation and further details on profitability.